About the Company
esperion therapeutics, inc. is a pharmaceutical company focused on developing and commercializing first-in-class, oral, ldl-c lowering therapies for the treatment of patients with hypercholesterolemia. etc-1002, the company's lead product candidate, is an inhibitor of atp citrate lyase, a well-characterized enzyme on the cholesterol biosynthesis pathway; the same pathway that includes hmg-coa reductase, the enzyme target of statins. the company has successfully completed its phase 1 and phase 2 development programs for etc-1002, and plans to initiate its etc-1002 phase 3 development program by the end of 2015. for more information, please visit www.esperion.com.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ESPR News
Q4 2023 Esperion Therapeutics Inc Earnings Call
Alexis Callahan; IR; Esperion Therapeutics, Inc. Sheldon Koenig; President & CEO; Esperion Therapeutics, Inc. Ben Halladay; CFO; Esperion Therapeutics, Inc. Eric ...
Esperion Therapeutics Stock (NASDAQ:ESPR), Quotes and News Summary
Here Are Other Stocks Moving In Friday's Mid-Day Session Shares of TransCode Therapeutics, Inc. (NASDAQ: RNAZ) fell sharply during Friday’s session. TransCode Therapeutics priced a 5,942,623 ...
Esperion Therapeutics Inc ESPR
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript February 27, 2024 Esperion Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.5, expectations were $-0.53.
Esperion Therapeutics Inc 0ET
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript
Esperion Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.5, expectations were $-0.53. Esperion Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at ...
Esperion Therapeutics Inc (ESPR)
Esperion Therapeutics (NASDAQ:ESPR) has announced a robust performance for the fourth quarter and the full year, marked by a significant 72% increase in total revenue ...
Esperion Therapeutics, Inc. (ESPR) Q4 2023 Earnings Call Transcript
Good morning, ladies and gentlemen. Thank you for standing by. Welcome to Esperion’s Fourth Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Loading the latest forecasts...